{
  "id": 10060775,
  "title": "2 Healthcare Stocks That Just Delivered Great News for Investors",
  "url": "https://urgent.news/2026/09/26/2-healthcare-stocks-that-just-delivered-great-news-for-investors",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-26T20:01:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/26/2-healthcare-stocks-that-just-delivered-great-news-for-investors/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Two healthcare stocks, Vertex Pharmaceuticals (VRTX) and Amgen (AMGN), have recently delivered positive news for investors. While both companies have outperformed the broader market this year, there may still be an opportune moment to invest in their stocks. Recent developments suggest that these pharmaceutical companies possess robust pipelines and attractive medium-term prospects.\n\nVertex Pharmaceuticals, specializing in the treatment of cystic fibrosis (CF), a rare and lifelong illness affecting patients' lungs and digestive systems, has demonstrated a healthy business model. The company consistently generates revenue and earnings from its medicines, which are considered the standard of care for CF patients. Since these patients must take the medications indefinitely, Vertex Pharmaceuticals enjoys strong pricing power and a relatively predictable revenue stream.\n\nSimilarly, Amgen (AMGN) has also shown impressive performance this year. As investors consider their options, it may be advantageous to take a closer look at both Vertex Pharmaceuticals and Amgen. These drugmakers possess strong pipelines and present attractive medium-term prospects, making them compelling investment opportunities.",
  "summary": "And there could be more positive developments ahead.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}